SEC Comment Letter for RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643) (RLMD) — Aug 18, 2020
RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643)
Date: Aug. 18, 2020 · CIK: 0001553643 · Accession: 0000000000-20-007613
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-245054
Letter
United States securities and exchange commission logo August 18, 2020 Sergio Traversa Chief Executive Officer Relmada Therapeutics, Inc. 880 Third Avenue, 12th Floor New York, NY 10022 Re:Relmada Therapeutics, Inc. Registration Statement on Form S-3 Filed August 12, 2020 File No. 333-245054 Dear Mr. Traversa: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Deanna Virginio at 202-551-4530 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Barrett DiPaolo, Esq.
Show Raw Text
United States securities and exchange commission logo
August 18, 2020
Sergio Traversa
Chief Executive Officer
Relmada Therapeutics, Inc.
880 Third Avenue, 12th Floor
New York, NY 10022
Re:Relmada Therapeutics, Inc.
Registration Statement on Form S-3
Filed August 12, 2020
File No. 333-245054
Dear Mr. Traversa:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Deanna Virginio at 202-551-4530 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Barrett DiPaolo, Esq.